7.68
Corvus Pharmaceuticals Inc stock is traded at $7.68, with a volume of 1.04M.
It is down -4.48% in the last 24 hours and up +6.82% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$8.04
Open:
$7.89
24h Volume:
1.04M
Relative Volume:
1.32
Market Cap:
$572.27M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-13.71
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-2.29%
1M Performance:
+6.82%
6M Performance:
+112.15%
1Y Performance:
-15.60%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CRVS
Corvus Pharmaceuticals Inc
|
7.68 | 599.09M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus to present final data on T cell lymphoma drug at ASH meeting - Investing.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikesTrade Signal Summary & High Win Rate Trade Tips - newser.com
Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan
Corvus Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockDip Buying & Stepwise Trade Signal Implementation - newser.com
Real time social sentiment graph for Corvus Pharmaceuticals Inc.2025 Performance Recap & Entry Point Strategy Guides - newser.com
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Why Corvus Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming base2025 Big Picture & Verified Entry Point Signals - newser.com
What momentum indicators show for Corvus Pharmaceuticals Inc. stockJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.Quarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm
Corvus Pharmaceuticals Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Corvus Pharmaceuticals, Inc. (CRVS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Corvus Pharmaceuticals, Inc. (CRVS) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Corvus Pharmaceuticals Inc. stock momentum explained2025 Analyst Calls & Precise Buy Zone Tips - newser.com
ETFs Investing in Corvus Pharmaceuticals, Inc. Stocks - TradingView
Will Corvus Pharmaceuticals Inc. stock benefit from green energy trendsEarnings Risk Report & Growth Focused Entry Reports - Fundação Cultural do Pará
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to host Nov. 4 webcast for financial results update - Stock Titan
How Corvus Pharmaceuticals Inc. stock reacts to Fed rate cuts - fcp.pa.gov.br
Will Corvus Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & AI Based Trade Execution Alerts - fcp.pa.gov.br
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Analyst Downgrade & Safe Swing Trade Setup Alerts - newser.com
Aug Summary: Why Corvus Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Selloffs & Real-Time Stock Price Movement Reports - fcp.pa.gov.br
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):